

Finally, as dopamine has been considered to take part in the seizure control system, our results suggest that recurrent seizures could induce an increase in the turnover in dopamine, resulting in a secondary depletion in striatum and SN.

*Franck Semah, Viviane Bouilleret, Maria-Joao Ribeiro, Orsay, France*

*Disclosure:* The authors report no disclosures.

Copyright © 2008 by AAN Enterprises, Inc.

1. Bouilleret V, Semah F, Chassoux F, et al. Basal ganglia involvement in temporal lobe epilepsy: a functional and morphologic study. *Neurology* 2008;70:177–184.
2. Goldstein DS, Nadi NS, Stull R, Wyler AR, Porter RJ. Levels of catechols in epileptogenic and non-epileptogenic regions of the human brain. *J Neurochem* 1988;50:225–229.
3. Ribeiro MJ, Vidailhet M, Loc'h C, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. *Arch Neurol* 2002;59:580–586.
4. Deransart C, Le-Pham BT, Hirsch E, Marescaux C, Depaulis A. Inhibition of the substantia nigra suppresses absences and clonic seizures in audiogenic rats, but not tonic seizures: evidence for seizure specificity of the nigral control. *Neuroscience* 2001;105:203–211.
5. Deransart C, Riban V, Lê B, Marescaux C, Depaulis A. Dopamine in the striatum modulates seizures in a genetic model of absence epilepsy in the rat. *Neuroscience* 2000;100:335–344.
6. Depaulis A, Moshé SL. The basal ganglia and the epilepsies: translating experimental concepts to new therapies. *Epileptic Disord* 2002;4(suppl 3):S7–S93.
7. Starr MS. The role of dopamine in epilepsy. *Synapse* 1996;22:159–194.

### CORRECTION

#### Are initial demyelinating event recovery and time to second event under differential control?

In the article “Are initial demyelinating event recovery and time to second event under differential control?” by T. West et al. (*Neurology*® 2006;67:809–813), the authors concluded from their statistical analysis that the disease-modifying therapy conferred an increased risk of a second event. On repeat analysis, they discovered that the numerator and denominator had been reversed and that the disease-modifying therapy actually conferred decreased risk of a second event. The univariate HR should have been reported as 0.38 with a 95% confidence interval from 0.23 to 0.62. This error does not change the other results of the study. The authors regret the error.

### CORRECTION

#### Familiality in brain tumors

In the article “Familiality in brain tumors” by Deborah T. Blumenthal and Lisa A. Cannon-Albright (*Neurology*® 2008; 71:1015–1020), the titles of tables 1 and 2 are incorrect. They should read as follows:

**Table 1** Relative risks for brain tumor among first-degree relatives of patients with brain tumor

**Table 2** Relative risks for brain tumor among second-degree relatives of patients with brain tumor

The publisher apologizes for the errors.

# Neurology<sup>®</sup>

## CORRECTION

*Neurology* 2008;71;1841-1841-a  
DOI 10.1212/01.wnl.0000339384.07826.f8

**This information is current as of November 24, 2008**

**Updated Information & Services**

including high resolution figures, can be found at:  
<http://n.neurology.org/content/71/22/1841.2.full>

**Permissions & Licensing**

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
[http://www.neurology.org/about/about\\_the\\_journal#permissions](http://www.neurology.org/about/about_the_journal#permissions)

**Reprints**

Information about ordering reprints can be found online:  
<http://n.neurology.org/subscribers/advertise>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

